Results 91 to 100 of about 74,894 (279)

Frontline ATRA‐ATO Therapy for Acute Promyelocytic Leukemia in Japan: Results From the Prospective Multicenter FBMTG‐APL2017 Trial

Cancer Science, EarlyView.
FBMTG‐APL2017: First prospective multicenter trial evaluating frontline ATRA‐ATO therapy for newly diagnosed APL in Japan, encompassing both low–intermediate (n = 65) and high‐risk (n = 16) patients. Excellent outcomes (95% CR, 94% 3‐year DFS) with comparable efficacy between risk groups (DFS: 97% vs.
Ken Takase, Tomohiko Kamimura, Takuro Kuriyama, Takahito Tokuyama, Hideho Henzan, Yoshikane Kikushige, Ilseung Choi, Yutaka Imamura, Akio Mori, Shuki Ohya, Noriaki Kawano, Koji Yonemoto, Mine Harada, Koichi Akashi, Toshihiro Miyamoto   +14 more
wiley   +1 more source

A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy

American journal of hematology/oncology, 2017
Hydroxyurea has proven clinical benefits and is recommended to be offered to all children with sickle cell anemia (SCA), but the optimal dosing regimen remains controversial. Induction of red blood cell fetal hemoglobin (HbF) by hydroxyurea appears to be
J. Estepp, M. Smeltzer, G. Kang, Chen Li, Winfred C. Wang, Christina M. Abrams, B. Aygun, R. Ware, K. Nottage, J. Hankins   +9 more
semanticscholar   +1 more source

Longitudinal Analysis of Sleep‐Disordered Breathing and Cognitive Outcomes in Children Living With Sickle Cell Anaemia

Clinical Otolaryngology, EarlyView.
ABSTRACT Objectives Sleep‐disordered breathing (SDB) and cognitive challenges are commonly observed in children living with sickle cell anaemia (SCA). This study investigated the longitudinal change in polysomnographic outcomes and the association with cognitive functions in children living with SCA.
Shifa Hamdule, Melanie Koelbel, Johanna C. Gavlak, Sati Sahota, Fenella J. Kirkham, Anna M. Hood   +5 more
wiley   +1 more source

Exploring barriers and strategies for hydroxyurea uptake using the CFIR–ERIC framework: A qualitative study of sickle cell disease in India

Clinical Epidemiology and Global Health
Problem considered: Hydroxyurea therapy is the cornerstone in treating sickle cell disease (SCD). However, the adherence to hydroxyurea by individuals with SCD is limited, owing to several barriers at multiple levels.
Vandana Mullakkal Venugopalan, Anindita Banerjee, Nithin Rajamani, Ravi Gajbhiye, Manisha Madkaikar, Naveen Khargekar   +5 more
doaj   +1 more source

Barriers to hydroxyurea adherence and health‐related quality of life in adolescents and young adults with sickle cell disease

European Journal of Haematology, 2017
To identify barriers to hydroxyurea adherence (negative beliefs, access, and/or recall barriers), and their relationship to adherence rates and health‐related quality of life (HRQOL) among adolescents and young adults (AYA) with sickle cell disease (SCD).
S. Badawy, A. Thompson, F. Penedo, J. Lai, K. Rychlik, R. Liem   +5 more
semanticscholar   +1 more source

Cell division promotes efficient retrotransposition in a stable L1 reporter cell line [PDF]

, 2013
Background: Long interspersed element type one (L1) actively modifies the human genome by inserting new copies of itself. This process, termed retrotransposition, requires the formation of an L1 ribonucleoprotein (RNP) complex, which must enter the ...
An, Wenfeng, Ivics, Zoltán, Izsvák, Zsuzsanna, Martin, Sandra L., Mátés, Lajos, Xie, Yi   +5 more
core   +2 more sources

Hydroxyurea use among children with sickle cell anemia

Pediatric Blood & Cancer, 2019
This study describes hydroxyurea use among children ages 1 to 17 with sickle cell anemia (SCA) enrolled in at least one year of Medicaid in six states from 2005 to 2012.
Sarah L. Reeves, Hannah K Jary, Jennifer P Gondhi, J. Raphael, L. Lisabeth, K. Dombkowski   +5 more
semanticscholar   +1 more source

Pulmonary hypertension in adolescents with sickle cell disease [PDF]

, 2016
Sickle cell disease consists of a group of disorders that have a similar mutation in at least one of the beta-globin chains of hemoglobin. This results in a change of the hemoglobin to sickle shaped cells when in the deoxygenated state.
Akinyemi, Katherine
core   +1 more source

Polycythemia Vera and Essential Thrombocythemia: A Nationwide Population‐Based Study on Treatment Patterns, Vascular Complications and Survival

European Journal of Haematology, EarlyView.
ABSTRACT Background Polycythemia vera (PV) and essential thrombocythemia (ET) are associated with a well‐recognized increased risk of thrombotic events, bleeding, and all‐cause mortality, but the frequency of these outcomes during treatment has rarely been assessed in large cohorts.
Anneli Enblom Larsson, Henrik Renlund, Björn Andréasson, Henrik Holmberg, Maria Liljeholm, Anders Själander   +5 more
wiley   +1 more source

Development of the InCharge Health Mobile App to Improve Adherence to Hydroxyurea in Patients With Sickle Cell Disease: User-Centered Design Approach

JMIR mHealth and uHealth, 2020
BackgroundSickle cell disease (SCD) is an inherited blood disorder causing acute complications and chronic progressive end organ damage. SCD is associated with significant morbidity, early mortality, impaired health-related quality of life, and increased
Alberts, Nicole M, Badawy, Sherif M, Hodges, Jason, Estepp, Jeremie H, Nwosu, Chinonyelum, Khan, Hamda, Smeltzer, Matthew P, Homayouni, Ramin, Norell, Sarah, Klesges, Lisa, Porter, Jerlym S, Hankins, Jane S   +11 more
doaj   +1 more source